Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial

American Heart Journal

Volumn 174, Issue , 2016, Pages 103-110

  Holman, Rury R ^a   Bethel, Mary Angelyn ^a   George, Jyothis ^a   Sourij, Harald ^a   Doran, Zoë ^a   Keenan, Joanne ^a   Khurmi, Nardev S ^c   Mentz, Robert J ^b   Oulhaj, Abderrahim ^a   Buse, John B ^d   Chan, Juliana C ^e   Iqbal, Nayyar ^f   Kundu, Sudeep ^f   Maggioni, Aldo P ^g   Marso, Steven P ^h   Öhman, Peter ^c   Pencina, Michael J ^b   Poulter, Neil ⁱ   Porter, Lisa E ^j   Ramachandran, Ambady ^k   Zinman, Bernard ^l   Hernandez, Adrian F ^b   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f BRISTOL MYERS SQUIBB   (United States)

^g ANMCO RESEARCH CENTER   (Italy)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

^j Dance Biopharm Inc   (United States)

^k Dr A Ramachandran's Diabetes Hospitals   (India)

^l MOUNT SINAI HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; MICROSPHERE; PEPTIDE; VENOM;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RISK REDUCTION; STUDY DESIGN; AGED; BLOOD; CARDIOVASCULAR DISEASES; CHINA; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GREAT BRITAIN; INCIDENCE; ITALY; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; ONTARIO; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; TIME FACTOR; TRENDS; UNITED STATES;

ADULT; AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHINA; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE 1; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; ITALY; MALE; MICROSPHERES; MIDDLE AGED; ONTARIO; PEPTIDES; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; UNITED STATES; VENOMS;

EID: 84977480444     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.12.009     Document Type: Article

References (38)

1. [1] Danaei, G., Finucane, M.M., Lu, Y., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378 (2011), 31–40.
2. [2] Stamler, J., Vaccaro, O., Neaton, J.D., et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993), 434–444.
3. [3] Seshasai, S.R., Kaptoge, S., Thompson, A., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364 (2011), 829–841.
4. [4] Turner, R.C., Millns, H., Neil, H.A., et al. Risk factors for coronary artery disease in non–insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316 (1998), 823–828.
5. [5] Sarwar, N., Gao, P., Seshasai, S.R., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375 (2010), 2215–2222.
6. [6] Fox, C.S., Coady, S., Sorlie, P.D., et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115 (2007), 1544–1550.
7. [7] Buse, J.B., Drucker, D.J., Taylor, K.L., et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 33 (2010), 1255–1261.
8. [8] Bergenstal, R.M., Wysham, C., Macconell, L., et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376 (2010), 431–439.
9. [9] Bunck, M.C., Diamant, M., Eliasson, B., et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 33 (2010), 1734–1737.
10. [10] Blevins, T., Pullman, J., Malloy, J., et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 96 (2011), 1301–1310.
11. [11] Russell-Jones, D., Cuddihy, R.M., Hanefeld, M., et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 35 (2012), 252–258.
12. [12] Nikolaidis, L.A., Mankad, S., Sokos, G.G., et al. Effects of glucagon-like peptide–1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004), 962–965.
13. [13] Koska, J., Schwartz, E.A., Mullin, M.P., et al. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care 33 (2010), 1028–1030.
14. [14] Lonborg, J., Vejlstrup, N., Kelbaek, H., et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 33 (2012), 1491–1499.
15. [15] Ratner, R., Han, J., Nicewarner, D., et al. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol, 10, 2011, 22, 10.1186/1475-2840-10-22.
16. [16] Best, J.H., Hoogwerf, B.J., Herman, W.H., et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 34 (2011), 90–95.
17. [17] Robinson, L.E., Holt, T.A., Rees, K., et al. Effects of exenatide and liraglutide on heart rate, blood pressure, and body weight: systematic review and meta-analysis. BMJ Open, 3, 2013, 10.1136/bmjopen-2012- 001986 [pii:e001986].
18. [18] DeYoung, M.B., MacConell, L., Sarin, V., et al. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 13 (2011), 1145–1154.
19. [19] Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide–1 receptor agonists and dipeptidyl peptidase–4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
20. [20] Tunis, S.R., Stryer, D.B., Clancy, C.M., Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 290 (2003), 1624–1632.
21. [21] EuroQol Group, EQ-5D user guide. A measure of health-related quality of life developed by the EuroQol Group. 1996, EuroQol Business Management, Erasmus University, Rotterdam.
22. [22] Rossing, P., Rossing, K., Gaede, P., et al. Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. Diabetes Care 29 (2006), 1024–1030.
23. [23] Linnebjerg, H., Kothare, P.A., Park, S., et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 64 (2007), 317–327.
24. [24] Bjerre Knudsen, L., Madsen, L.W., Andersen, S., et al. Glucagon-like peptide–1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151 (2010), 1473–1486.
25. [25] Food and Drug Administration, Pharmacology review Byetta. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_Byetta_pharmr.pdf, 2005 [Accessed March 8, 2015.].
26. [26] Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available at: http://www.fda.gov/downloads/Drugs/NewsEvents/UCM209087.pdf [Accessed September 9, 2014.].
27. [27] Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
28. [28] White, W.B., Cannon, C.P., Heller, S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
29. [29] Ban, K., Noyan-Ashraf, M.H., Hoefer, J., et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor–dependent and –independent pathways. Circulation 117 (2008), 2340–2350.
30. [30] Arakawa, M., Mita, T., Azuma, K., et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide–1 receptor agonist, exendin-4. Diabetes 59 (2010), 1030–1037.
31. [31] Bormann, B.T., Homann, P.S., Darbyshire, R.L., et al. Intense forest wildfire sharply reduces mineral soil C and N: the first direct evidence. Can J For Res 38 (2008), 2771–2783.
32. [32] Ozyazgan, S., Kutluata, N., Afsar, S., et al. Effect of glucagon-like peptide–1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. Pharmacology 74 (2005), 119–126.
33. [33] Bose, A.K., Mocanu, M.M., Carr, R.D., et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54 (2005), 146–151.
34. [34] Nikolaidis, L.A., Elahi, D., Shen, Y.T., et al. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289 (2005), H2401–H2408.
35. [35] Sokos, G.G., Nikolaidis, L.A., Mankad, S., et al. Glucagon-like peptide–1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12 (2006), 694–699.
36. [36] Butler, P.C., Elashoff, M., Elashoff, R., et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?. Diabetes Care 36 (2013), 2118–2125.
37. [37] Nauck, M.A., A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care 36 (2013), 2126–2132.
38. [38] Bethel, M.A., Sourij, H., Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice. Curr Cardiol Rep 14 (2012), 59–69.